Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials (i2TEAMM)

Individual-patient meta-analysis from 20 randomized trials; 11 studies (4,773 patients) evaluated 9- or 12-month MRD-CR at a 10^-5 threshold as an intermediate endpoint for PFS/OS in ND transplant-eligible, ND transplant-ineligible, and RRMM. Patient-level global ORs for MRD-CR and PFS ranged from 3.06 to 16.24 (all 95% CIs excluded 1.0). Trial-level R² 0.61-0.70 overall and 0.67-0.78 in newly diagnosed disease. Supported use of 9- or 12-month MRD-CR at 10^-5 as an intermediate endpoint for accelerated approval. This is the i2TEAMM pooled analysis presented at ODAC.

J Clin OncolPubMed 39938021